Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)

PHASE3CompletedINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

December 3, 2018

Primary Completion Date

February 25, 2019

Study Completion Date

February 25, 2019

Conditions
Dry Eye
Interventions
DRUG

Brimonidine Tartrate

Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks.

DRUG

Placebos

Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks.

Trial Locations (16)

16066

Scott and Christie Eyecare Associates, Cranberry Township

33064

Rand Eye Institute, Pompano Beach

37215

Toyos Clinic, Nashville

38119

Total Eye Care, Memphis

44115

Abrams Eye Center, Cleveland

45236

Apex Eye- Kenwood, Cincinnati

45242

Apex Eye-Montgomery, Cincinnati

60169

Chicago Cornea Consultants, Hoffman Estates

63131

Ophthalmology Associates, St Louis

66204

Heart of America Eye Care, P. A., Mission

77004

Midtown Eye Physicans & Associates, Houston

77034

Advanced Laser Vision & Surgical Institute, Houston

78734

Revolution Research, Inc; Lake Travis Eye and Laser Center, Lakeway

84107

The Eye Institute of Utah, Salt Lake City

92663

Aesthetic Eye Care Institute/David Wirta, MD and Associates, Newport Beach

95670

Martel Medical Eye Group, Rancho Cordova

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ocugen

INDUSTRY

NCT03785340 - Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED) | Biotech Hunter | Biotech Hunter